1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Navigating discrepancies : The assessment of residual lymphovascular invasion in breast carcinoma after neoadjuvant treatment
- Contribution to journal › Article
-
Mark
Short-term outcomes from the 'Watch and Wait' (WoW) study : prospective cohort study
- Contribution to journal › Article
- 2024
-
Mark
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer - Principles of Classification and Emerging Clinical Utility
- Contribution to journal › Article
- 2023
-
Mark
Predictive biomarkers in radioresistant rectal cancer : A systematic review
- Contribution to journal › Scientific review
- 2022
-
Mark
Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients : proof of concept
- Contribution to journal › Article
-
Mark
Effect of sex on survival after resection of oesophageal cancer : nationwide cohort study
- Contribution to journal › Article
- 2021
-
Mark
Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer : study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)
- Contribution to journal › Article
- 2020
-
Mark
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer : a national cohort study
- Contribution to journal › Article
-
Mark
Mammographic density changes during neoadjuvant breast cancer treatment : NeoDense, a prospective study in Sweden
- Contribution to journal › Article
-
Mark
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
- Contribution to journal › Article
